行情

VTGN

VTGN

VistaGen
NASDAQ

实时行情|Nasdaq Last Sale

0.6823
-0.0040
-0.58%
盘后: 0.6823 0 0.00% 17:46 02/20 EST
开盘
0.8000
昨收
0.6863
最高
0.8675
最低
0.6578
成交量
239.07万
成交额
--
52周最高
1.513
52周最低
0.2943
市值
3,272.52万
市盈率(TTM)
-1.1319
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VTGN 新闻

  • 《消费者报告》首次将特斯拉Model 3列为"首选车型"
  • 新浪美股.7小时前
  • 低利率的大背景下 市政债券或成“新贵”
  • 新浪财经-自媒体综合.8小时前
  • 巴以双方解除农产品贸易禁令
  • 新华网.9小时前
  • 联储二号人物给交易员"泼冷水" 这次市场共识又错了?
  • FX168.9小时前

更多

所属板块

制药
-0.54%
制药与医学研究
-0.40%

热门股票

名称
价格
涨跌幅

VTGN 简况

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
展开

Webull提供Vistagen Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。